• 1
    Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26: 681686.
  • 2
    Boehler A, Estenne M. Posttransplant bronchiolitis obliterans. Eur Respir J 2003; 22: 10071018.
  • 3
    Trulock EP, Christie JD, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26: 782795.
  • 4
    Palmer SM, Davis RD, Hadjiliadis D et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799804.
  • 5
    Reznik SI, Jaramillo A, SivaSai KS et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001; 1: 228235.
  • 6
    Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 17761784.
  • 7
    Willis BC, DuBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006; 3: 377382.
  • 8
    Serini G, Bochaton-Piallat ML, Ropraz P et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142: 873881.
  • 9
    Willis BC, Borok Z. TGF-beta-induced EMT: Mechanisms and implications for fibrotic lung disease. Am J Physiol 2007; 293: L525L534.
  • 10
    Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005; 16: 6878.
  • 11
    El-Gamel A, Sim E, Hasleton P et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828837.
  • 12
    Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297310.
  • 13
    Hodge SJ, Hodge GL, Reynolds PN, Holmes MD. Differential rates of apoptosis in bronchoalveolar lavage and blood of lung transplant patients. J Heart Lung Transplant 2005; 24: 13051314.
  • 14
    Hodge S, Hodge G, Holmes M, Reynolds PN. Flow-cytometric characterisation of cell populations in bronchoalveolar lavage (BAL) and bronchial brushings from patients with chronic obstructive pulmonary disease (COPD). Cytometry 2004; 61B: 2734.
  • 15
    Ward C, Effros RM, Walters EH. Assessment of epithelial lining fluid dilution during bronchoalveolar lavage. Eur Respir Rev 1999; 9: 3237.
  • 16
    Ward C, Forrest IA, Murphy DM et al. The phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005; 60: 865871.
  • 17
    Mamessier E, Lorec AM, Thomas P, Badier M, Magnan A, Reynaud-Gaubert M. T regulatory cells in stable posttransplant bronchiolitis obliterans syndrome. Transplantation 2007; 84: 908916.
  • 18
    Myerburg MM, Latoche JD, McKenna EE et al. Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells. Am J Physiol 2007; 292: L1352L1360.
  • 19
    Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet 2004; 363: 15031508.
  • 20
    Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96107.